The deal size was increased to $275M from $200M and priced below last closing price of $16.94. BofA, SVB Securities and Evercore ISI are acting as joint book running managers for the offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ETNB:
- 89bio, Inc. Announces Upsized Pricing of $275 Million Public Offering of Common Stock
- Morgan Stanley stays Overweight Akero Therapeutics after 89bio data in NASH
- 89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
- 89bio announces $200M common stock offering
- 89bio price target raised to $33 from $18 at Oppenheimer